Neurological Complications of Biological Treatment of Psoriasis

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Jan 21

PMID 35054511

Authors

Mateusz Kamil Ozog

Beniamin Oskar Grabarek

Magdalena Wierzbik-Stronska

Magdalena Swider

Affiliations

Soon will be listed here.

Abstract

In the available literature, little attention has been paid to the assessment of psoriasis and the biological therapy used for it and the nervous system. The purpose of this article is to discuss the relationship between psoriasis and the nervous system as well as to analyze the mechanisms that lead to neurological complications during anticytokine therapies in psoriasis. However, this connection requires further analysis. The use of biological drugs in psoriasis, although it yields positive therapeutic results, is not without numerous side effects. Serious neurological side effects of the therapy are most often visible with the use of anti-TNF-alpha, which is why patients should be monitored for their potential occurrence. Early detection of complications and rapid discontinuation of treatment with the drug may potentially increase the patient's chances of a full recovery or improvement of his/her neurological condition. It also seems reasonable that, in the case of complications occurring during anti-TNF-alpha therapy, some of the drugs from other groups should be included in the therapy.

Citing Articles

Transverse Myelitis: An Adverse Reaction to Abatacept.

Adelakun A, Haddad A, Mirza N, Dover M, Golombek S Cureus. 2024; 16(4):e59201.

PMID: 38807813 PMC: 11130530. DOI: 10.7759/cureus.59201.

Expression profile of mRNAs and miRNAs related to mitogen-activated kinases in HaCaT cell culture treated with lipopolysaccharide a and adalimumab.

Wojcik M, Plata-Babula A, Glowaczewska A, Sirek T, Orczyk A, Malecka M Cell Cycle. 2024; 23(4):385-404.

PMID: 38557266 PMC: 11174132. DOI: 10.1080/15384101.2024.2335051.

Gene expression profile of mitogen-activated kinases and microRNAs controlling their expression in HaCaT cell culture treated with lipopolysaccharide A and cyclosporine A.

Wojcik M, Zmarzly N, Derkacz A, Kulpok-Baginski T, Blek N, Grabarek B Cell Cycle. 2024; 23(3):279-293.

PMID: 38445655 PMC: 11057563. DOI: 10.1080/15384101.2024.2320508.

Impact of Alcohol Consumption, Smoking, and Diet on the Severity of Plaque Psoriasis: A Comprehensive Assessment using Clinical Scales and Quality of Life Measures.

Michalski P, Palazzo-Michalska V, Michalska-Bankowska A, Bankowski M, Grabarek B Med Sci Monit. 2023; 29:e941255.

PMID: 37528577 PMC: 10405633. DOI: 10.12659/MSM.941255.

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers.

Delcoigne B, Kopp T, Arkema E, Hellgren K, Provan S, Relas H RMD Open. 2023; 9(1).

PMID: 36854568 PMC: 9980369. DOI: 10.1136/rmdopen-2022-002924.

References

Dattola A, Silvestri M, Tamburi F, Amoruso G, Bennardo L, Nistico S . Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising. Dermatol Ther. 2020; 33(6):e14504. DOI: 10.1111/dth.14504. View

Kaltsonoudis E, Voulgari P, Konitsiotis S, Drosos A . Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2013; 13(1):54-8. DOI: 10.1016/j.autrev.2013.09.002. View

Bornstein G, Ben-Zvi I, Furie N, Grossman C . Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis. Int J Rheum Dis. 2019; 22(5):940-945. DOI: 10.1111/1756-185X.13483. View

Farukhi F, Bollinger K, Ruggieri P, Lee M . Infliximab-associated third nerve palsy. Arch Ophthalmol. 2006; 124(7):1055-7. DOI: 10.1001/archopht.124.7.1055. View

Nussbaum L, Chen Y, Ogg G . Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2020; 184(1):14-24. DOI: 10.1111/bjd.19380. View

Yao A, Chan H, Macdonell R, Shuey N, Khong J . Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. Clin Neurol Neurosurg. 2017; 164:64-66. DOI: 10.1016/j.clineuro.2017.11.001. View

Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L . Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013; 7(10):769-79. DOI: 10.1016/j.crohns.2013.01.009. View

Nicocia G, Bonanno C, Lupica A, Toscano A, Rodolico C . Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: A case report. Neuromuscul Disord. 2020; 30(3):246-249. DOI: 10.1016/j.nmd.2020.01.001. View

Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T . Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017; 13(10):2247-2259. PMC: 5647990. DOI: 10.1080/21645515.2017.1356498. View

10.

Chen M, Ku Y, Yip H, Cheng-Chung Wei J . Tonsillectomy and the subsequent risk of psoriasis: A nationwide population-based cohort study. J Am Acad Dermatol. 2021; 85(6):1493-1502. DOI: 10.1016/j.jaad.2021.01.094. View

11.

Reich K, Armstrong A, Langley R, Flavin S, Randazzo B, Li S . Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394(10201):831-839. DOI: 10.1016/S0140-6736(19)31773-8. View

12.

Findeisen K, Sewell J, Ostor A . Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. Biologics. 2021; 15:343-352. PMC: 8370108. DOI: 10.2147/BTT.S252575. View

13.

Rowin J . Etanercept treatment in myasthenia gravis. Ann N Y Acad Sci. 2008; 1132:300-4. DOI: 10.1196/annals.1405.028. View

14.

Noisette A, Hochberg M . Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl). 2018; 8:31-39. PMC: 6047621. DOI: 10.2147/PTT.S146076. View

15.

Silfvast-Kaiser A, Homan K, Mansouri B . A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis (Auckl). 2019; 9:81-90. PMC: 6709810. DOI: 10.2147/PTT.S186637. View

16.

Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P . Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol. 2011; 147(10):1197-202. DOI: 10.1001/archdermatol.2011.161. View

17.

Pittam B, Gupta S, Harrison N, Robertson S, Hughes D, Zhao S . Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2020; 59(9):2199-2206. DOI: 10.1093/rheumatology/keaa062. View

18.

Passante M, Dastoli S, Nistico S, Bennardo L, Patruno C . Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: A case report. Dermatol Ther. 2019; 33(1):e13170. DOI: 10.1111/dth.13170. View

19.

Deepak P, Stobaugh D, Sherid M, Sifuentes H, Ehrenpreis E . Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2013; 38(4):388-96. DOI: 10.1111/apt.12385. View

20.

Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst D . Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015; 1(1):e000080. PMC: 4612693. DOI: 10.1136/rmdopen-2015-000080. View